

CORRECTION

Open Access



Correction to: SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion

Sarah Halford^{1*}, Susan Wan¹, Ilaria Dragoni¹, Julie Silvester¹, Bobojon Nazarov², Daniel Anthony³, Suzie Anthony⁴, Emma Ladds⁵, John Norrie⁶, Kevin Dhaliwal⁶ and the CDD SPIKE-1 Project Team¹

Correction to: *Trials* 22, 550 (2021)
<https://doi.org/10.1186/s13063-021-05461-9>

Following the publication of the original article [1], we were notified that the Flu-iiQ™ table included in the supplementary material of original publication needs to be deleted. The authors were not at liberty to publish the table in full as a number of the items listed are confidential and commercially sensitive. For full details of the Flu-iiQ™ questionnaire please contact Measured Solutions P/L, PO Box 5127, Alphington VIC 3079, Australia (measuredsolutions.com.au).

The original article has been corrected.

Author details

¹Cancer Research UK Centre for Drug Development, London, UK. ²Latus Therapeutics, London, UK. ³University of Oxford, Oxford, UK. ⁴Oxford University Hospitals NHS Foundation Trust, Oxford, UK. ⁵Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. ⁶The University of Edinburgh, Edinburgh, UK.

Published online: 21 April 2022

Reference

1. Halford, et al. SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion. *Trials*. 2021;22:550. <https://doi.org/10.1186/s13063-021-05461-9>.

The original article can be found online at <https://doi.org/10.1186/s13063-021-05461-9>.

* Correspondence: sarah.halford@cancer.org.uk

¹Cancer Research UK Centre for Drug Development, London, UK
Full list of author information is available at the end of the article



© The Author(s). 2022 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.